Affimed N.V. is a biotechnology company focused on developing immuno-oncology therapies, particularly its proprietary tetravalent bispecific antibodies designed to engage the immune system against cancer cells. The company operates primarily in the United States and Europe, with a pipeline that includes AFM13 and AFM24 targeting various hematological malignancies and solid tumors.
Affimed generates revenue primarily through partnerships and collaborations with larger pharmaceutical companies, leveraging its innovative antibody technology. The company has a strong intellectual property portfolio, which provides a competitive edge in the immuno-oncology space.
Progress in clinical trials for AFM13 and AFM24
Partnership announcements with major pharmaceutical companies
Regulatory approvals for new therapies
Market reception of data from clinical studies
Regulatory changes impacting drug approval processes
Technological disruption from new therapies or competitors
Emergence of new immuno-oncology therapies from competitors
Potential for larger pharmaceutical companies to develop similar technologies in-house
High cash burn rate affecting liquidity
Dependence on external funding for ongoing clinical trials
low - The biotechnology sector is generally less sensitive to economic cycles, as healthcare spending tends to remain stable regardless of economic conditions.
Moderate - Rising interest rates could increase the cost of capital for funding R&D, impacting future projects and valuations.
minimal - The company has a manageable debt level, and current credit conditions do not pose a significant risk.
growth - Investors are likely attracted to the potential for high returns from successful drug development.
high - The stock has historically shown high volatility due to binary outcomes associated with clinical trials.